Nepexto will be marketed in Australia by Biocon Biologics’ local partner, Generic Health, a leading supplier of high-quality generic prescription, injectable, and over-the-counter medicines. The partnership aims to broaden patient access to affordable treatment options in the country.
Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Nepexto received marketing authorisation in the European Union in 2020 and has since seen strong adoption across European markets.
Following its global acquisition and vertical integration of the biosimilars business in 2022, Biocon Biologics is leveraging this foundation to expand Nepexto into new markets and further strengthen its immunology portfolio.
Shares of Biocon Ltd. opened flat on Wednesday at ₹387.30. The stock has risen 5% so far in 2025.
